NEW YORK — Clinical informatics firm Ovation has struck a deal to use DNAnexus' Precision Health Data Cloud data management and analysis system with its collections of large-scale omics data, the companies said on Wednesday.
Ovation's omics data is generated from a biobank of over 1.6 million consented samples that are sourced from a nationwide network of CLIA-certified clinical diagnostic labs. Under the terms of the deal, Portland, Maine-based Ovation will initially use DNAnexus' system with its inflammatory bowel disease omics data, which includes whole-genome sequencing and whole-transcriptome sequencing on normal and diseased tissues linked to longitudinal clinical data.
The companies said they plan to later extend the arrangement to include Ovation's data collections in immunology, oncology, and cardiometabolic disease. Financial and other terms of the arrangement were not disclosed.
"The ability to manage and interpret omics data is crucial as computational methods are rapidly advancing," Ovation CEO Curt Medeiros said in a statement. The agreement with DNAnexus "is an exciting opportunity to advance our shared vision to improve therapeutic biomarker and target discovery and deliver on the promise of precision medicine for patients."
The deal with Ovation marks the latest DNAnexus has struck for access to its data management systems and follows partnerships with Fabric Genomics, Our Future Health, and Twist Bioscience, among others.